Veru (VERU) Q2 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Samuel Fisch - Executive Director of Investor Relations & Corporate CommunicationsMitchell Steiner - Chairman, President & CEOMichele Greco - CFO & Chief Administrative OfficerAnthea Li - Equity Research AssociateGary Nachman - Managing Director - Equity ResearchGary Barnette - Chief Scientific OfficerEduardo Martinez-Montes - Biotechnology Equity Research Associate Conference Call Participants William Wood - Equity Research Ana ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $42.7 million, representing a 72% year-over-year increase, with constant currency growth at 76% [8] - Gross profit reached $24.2 million, reflecting a gross margin of approximately 57%, a decline of 14 percentage points from the previous year [9] - Net loss was $300,000 or $0.00 per share, a decline of $4.2 million from the previous year [12] - Adjusted EBITDA declined by $300,000 or 5% to $5.6 million [12] - Cash and cash equivalents as of March 31, 2025, were $29.7 million, with a net debt leverage ratio under 1.6 turns [13] Business Line Data and Key Metrics Changes - The raffle business achieved record results, including all-time highs in revenue, ticket sales, and prize values, with a 46% increase in new users compared to Q1 2024 [6] - MeridianBet saw new registrations increase by 22%, first-time deposits surged over 56%, and total deposits rose 12% [15] Market Data and Key Metrics Changes - MeridianBet secured a permanent online betting license in Brazil, allowing full national coverage in a market projected to generate over $5.6 billion in GGR in 2025 [16] - The company launched B2B operations in Nigeria, tapping into a market with over 60 million bettors [16] Company Strategy and Development Direction - The company is focused on platform innovations and expansion into high-growth regulated markets, positioning itself at the forefront of the iGaming industry [5] - The strategy emphasizes smart growth, operational efficiency, and returning value to shareholders [20] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about growth opportunities for the year, expecting full-year revenue between $190 million and $195 million, representing a 26% to 29% growth rate over 2024 [21] - The company remains committed to disciplined capital allocation and investments that enhance growth and long-term value [21] Other Important Information - The company eliminated approximately $9.6 million in debt and converted over $9.5 million in acquisition-related debt into equity, enhancing financial strength and flexibility [6] - MeridianBet's community initiatives included 56 projects focused on health donations, scholarships, and responsible betting education [17] Q&A Session Summary Question: What are the growth expectations for the company in 2025? - The company expects full-year revenue to be between $190 million and $195 million, indicating a growth rate of 26% to 29% over 2024 [21] Question: How is the company addressing operational costs? - The increase in operating expenses is attributed to costs related to geographic expansion, market share improvement, and technology advancements [11]

Financial Data and Key Metrics Changes - The company reported record total revenue of $47 million for Q1 2025, up 5% year over year, with subscription revenue reaching $44.9 million, an increase of 9% year over year [5][21] - Adjusted EBITDA for the quarter was $4.1 million, marking the seventh consecutive quarter of adjusted EBITDA profitability [5][24] - Non-GAAP gross margin improved to 70%, up from 65% in the same quarter last year [6][24] - The company consumed $1 million in cash for operations during the quarter, consistent with the previous year [6][26] Business Line Data and Key Metrics Changes - In the Enterprise and Telecom (EENT) segment, total revenue was $34.4 million, up 6% year over year, with subscription revenue at $33.6 million, a 10% increase year over year [23] - In the Media and Telecom (M&T) segment, total revenue was $12.6 million, representing 2% year over year growth, with subscription revenue at $11.3 million, up 7% year over year [23][24] - Professional services revenue decreased significantly, down 42% year over year, contributing $2.1 million for the quarter [22] Market Data and Key Metrics Changes - The company experienced a gross retention rate in EENT at its best level since Q4 2022, while net dollar retention climbed to 107%, the highest since Q1 2022 [8][20] - The remaining performance obligations (RPO) were $184.9 million, down 9% sequentially but up 12% year over year [22] Company Strategy and Development Direction - The company aims to achieve double-digit revenue growth and a rule of 30 by 2028, focusing on consolidating video usage around its platform and enhancing AI capabilities [14][31] - Continued investment in AI to deliver hyper-personalized experiences is a key focus, with new product offerings like Genie agents and Content Lab enhancements [9][10] - The company plans to gradually increase its sales team after a previous reduction, focusing on enterprise markets while also reaccelerating efforts in media and education sectors [44][46] Management's Comments on Operating Environment and Future Outlook - Management noted that there has been no significant negative impact from the macroeconomic environment, with customers remaining stable in their spending [35][39] - The company expects a typical seasonal decline in Q2 revenue but anticipates a strong recovery in the second half of the year [27][29] - Management remains cautious about the uncertain macro outlook but is optimistic about the pipeline and growth opportunities [30][31] Other Important Information - The company hosted its first annual investor event, showcasing its profitable growth plans and AI-infused vision [14][15] - The company continues to receive recognition from leading analyst firms, including Gartner, for its video platform services [12][13] Q&A Session Summary Question: Customer spending trends and macroeconomic impact - Management indicated no material negative impact from customers regarding spending, noting that larger organizations are planning for the mid to long term [35][36] Question: Sales team resource allocation - The company plans to gradually increase sales resources, focusing on enterprise markets while also reaccelerating efforts in media and education [44][46] Question: Nature of M&T churn - Management clarified that the churn in M&T is expected and primarily involves a few accounts exiting rather than downsizing [50][51] Question: Product investment focus - The company is focusing on deeper solutions rather than self-service, with an emphasis on AI to enhance customer experiences [54][56] Question: Dynamics of higher ARR per customer - The increase in ARR per customer is driven by upselling and consolidation around Kaltura's products rather than price increases [73] Question: AI monetization strategy update - Management expressed excitement about the growing pipeline for AI products and expects to start monetizing these opportunities in the coming quarters [76][77]

Papa John’s International (PZZA) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Heather Hollander - SVP & Investor RelationsTodd Penegor - President & CEORavi Thanawala - EVP & CFO, InternationalPeter Saleh - MD - Restaurants Conference Call Participants Brian Bittner - Senior Equity Analyst - RestaurantsAndrew Strelzik - Equity Research AnalystEric Gonzalez - Senior Research Analyst - US RestaurantsJim Salera - Research AnalystSara Senatore - Senior Research AnalystBrian Mullan - Direc ...

Lesaka Technologies (LSAK) Q3 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Phillipe Welthagen - ED & Investor RelationsDan Smith - Group CFOSteven Heilbron - Head of Mergers, Acquisitions & Corporate DevelopmentLincoln Mali - CEO of Southern Africa & DirectorNaeem Kola - Group COOAli Mazanderani - Executive Chairman Phillipe Welthagen Welcome to Lusarcatec's webcast for the third quarter of fiscal twenty twenty five. As a reminder, the webcast is being recorded and the presentation can b ...

Financial Data and Key Metrics Changes - Alvotech raised its full-year revenue guidance for 2025 to $600 million to $700 million and adjusted EBITDA guidance to $200 million to $280 million [7][39] - The company achieved $110 million in product revenues during Q1 2025, an increase of $97 million or 784% compared to the same period in the prior year [30][31] - Adjusted EBITDA for Q1 2025 was $21 million, compared to negative adjusted EBITDA of $38 million for the same period in the prior year [39] Business Line Data and Key Metrics Changes - The Stellara biosimilar was launched in the U.S. market in late February 2025, following successful launches in Europe, Japan, and Canada [8][9] - Alvotech's biosimilar to Humira saw strong uptake in the U.S. market, with a penetration rate of at least 21% by year-end 2024 [20][21] - The company expects to move from two marketed biosimilars to six by early 2026, with three biosimilar filings under review in major markets [11][27] Market Data and Key Metrics Changes - In the U.S. market, Alvotech's Humira biosimilar represented about 12% of total demand for Humira and Humira biosimilars in 2024 [19][21] - The European Stellara market expanded by 9% year-over-year due to the entry of biosimilars, with Alvotech aiming for a double-digit market share by the end of 2025 [23] - Alvotech is the only developer to launch a Stellara biosimilar in Japan, indicating a strong competitive position in that market [24] Company Strategy and Development Direction - Alvotech plans to significantly increase the pace of development, moving four to six new biosimilar candidates into in-house process development each year [12] - The company is focused on a B2B model, which allows it to address a global patient population through 20 strategic commercial partnerships across 90 markets [12] - Alvotech aims to maintain a focus on quality and reliability rather than sacrificing value for market share in a competitive environment [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the Stellara biosimilar in the U.S. market, especially after receiving the interchangeable designation [45] - The company anticipates that if tariffs on pharmaceuticals are applied, they will not disrupt operations or competitiveness in the U.S. market [13] - Management expects to be free cash flow positive in 2025, marking a significant milestone for the company [40] Other Important Information - Alvotech's net debt stood at $1.058 billion as of March 31, 2025, with expectations of mid-single-digit leverage by year-end [41] - The company closed the period with 301.9 million shares outstanding, including unvested earn-out shares [42] Q&A Session Summary Question: Can you clarify the interchangeable exclusivity and its implications? - Management confirmed the receipt of the interchangeable designation and noted that while some competitors may also obtain it, this designation is expected to drive faster uptake of their product [45][46] Question: What is the impact of stocking on the Stellara biosimilar sales? - Management clarified that the sales figures are driven by timing of orders rather than stocking, as they operate on a B2B model [50][51]

Financial Data and Key Metrics Changes - Total revenues increased to $57.3 million in Q1 2025 from $32.6 million in Q1 2024, primarily driven by net product revenues which rose to $55.8 million from $31 million [22][25] - Net income for Q1 2025 was $6.1 million compared to a net loss of $18 million in Q1 2024, reflecting strong revenue growth [25][26] - Cost of goods sold decreased to $7.6 million in Q1 2025 from $11.6 million in Q1 2024, attributed to the full amortization of a non-cash charge related to Auryxia [23][24] Business Line Data and Key Metrics Changes - Vafcio generated $12 million in net product revenues in Q1 2025, exceeding guidance of $10 million to $11 million [6][22] - Auryxia net product revenues increased to $43.8 million in Q1 2025 from $31 million in Q1 2024, despite losing IP exclusivity [22][23] Market Data and Key Metrics Changes - The top five dialysis organizations have ordered Vafcio, with revenues primarily coming from small to mid-sized dialysis organizations treating approximately 150,000 patients [8][14] - The VOICE study is progressing towards full enrollment, with about 75% of the target 2,200 subjects enrolled [10] Company Strategy and Development Direction - The company aims to expand the use of Vafcio in both dialysis and non-dialysis patient populations, with plans to initiate a Phase III VALOR trial in the second half of 2025 [10][11] - The focus remains on increasing the breadth and depth of prescribing among current customers while unlocking new customers [21][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong early performance of Vafcio, highlighting the importance of prescriber education and patient retention [6][21] - The company is confident in its financial position and ability to achieve profitability based on its current operating plan [26][27] Other Important Information - The company ended Q1 2025 with $113.4 million in cash and cash equivalents, bolstered by a public offering that raised over $46 million [26] - The company has at least 12 months of Vafcio inventory on hand in the U.S. and does not expect significant tariff-related impacts [24] Q&A Session Summary Question: Update on timelines for adding Vafcio to protocols at large dialysis organizations - Management indicated that a large pilot is planned to operationalize protocols, with training expected to take about a month, followed by a pilot duration of two to three months [29][31][34] Question: Shift from Auryxia prescriptions to authorized generic - Management noted that the impact of the authorized generic has been minimal in Q1 2025, with expectations that it will not significantly affect business in Q2 [46][48][49] Question: Net price dynamics as large dialysis providers come on board - Management acknowledged that net prices may decrease as volumes increase, but there will be variability in pricing due to the competitive environment [53][55] Question: Demand drivers for Vafcio and reimbursement trends - Management highlighted that demand is driven by clinical efficacy and economic incentives, with positive trends in Medicare Advantage coverage [70][72][78] Question: Inventory stocking trends with large dialysis organizations - Management expects initial stocking for pilots but does not anticipate significant issues with inventory levels due to efficient distribution networks [84][88] Question: Market landscape for label expansion opportunities - Management expressed excitement about the non-dialysis market, which is comparable in size to the dialysis market, and emphasized the potential for significant revenue growth [90][92][94]

Financial Performance - Q1 2025 revenue was $215.1 million, a sequential decrease of 9.3% but a year-over-year increase of 3.7% [6][7] - Gross margin was 30.5%, consistent with guidance and up from 29.3% year-over-year [6][7] - Q1 profit per diluted ADS was $0.01, exceeding guidance due to lower operating expenses [7][12] - Operating income was $19.8 million, representing 9.2% of sales, compared to 4.8% a year ago [12] - Cash and cash equivalents were $281 million, up from $277.4 million a year ago [13] Business Line Performance - Revenue from large display drivers was $25 million, flat from the previous quarter, driven by demand from Chinese government subsidies [7][9] - Small and medium-sized display driver revenue totaled $150.5 million, reflecting a sequential decline of 9.8% [9][10] - Automotive driver IC sales rose nearly 20% year-over-year, making it the largest revenue contributor [10][11] - Non-driver sales reached $39.6 million, a 12.8% decrease from the previous quarter [10][11] Market Performance - Automotive IC sales showed resilience with a single-digit decline, while overall automotive driver IC sales rose nearly 20% year-over-year [9][10] - Smartphone and tablet driver sales declined as expected amid a subdued festival season [10][11] - The automotive market remains a key focus, with Himax holding a 40% share in DDIC and over 50% in TDDI [34][36] Company Strategy and Industry Competition - Himax is focusing on maintaining a healthy balance sheet while driving sustainable long-term growth through high dividends and share repurchases [15] - The company is deepening its supply chain in Taiwan and strengthening its presence in China, Korea, and Singapore to mitigate geopolitical risks [24][25] - Himax is committed to innovative fields such as ultra-low power AI, AR glasses, and co-packaged optics, which are expected to contribute to revenue growth [26][28] Management Commentary on Operating Environment and Future Outlook - Management expressed concerns about macroeconomic uncertainties and the impact of U.S. tariffs on customer demand [19][24] - The company anticipates a conservative revenue outlook for Q2 2025, reflecting cautious customer sentiment amid global economic uncertainties [24][60] - Despite challenges, Himax remains confident in its growth potential in new technology areas, particularly TDDI and TCOM [62] Other Important Information - The company announced an annual cash dividend of $0.037 per ADS, totaling $64.5 million, with a payout ratio of 81.1% of the previous year's profits [15] - Capital expenditures for Q1 were $5.2 million, primarily for R&D related equipment [15] Q&A Session Summary Question: Could you explain the validation process for CPO? - The validation process involves collaboration with leading customers and foundry partners, focusing on current and newly developed products [56] Question: Do you have guidance for 2025? - The company does not provide full-year guidance due to macroeconomic uncertainties but acknowledges low visibility for the second half of the year [59][60] Question: What is the outlook for the automotive market? - Management noted concerns about the effectiveness of future government stimulus programs in China and the potential impact on automotive demand [60][62] Question: Comment on the Obsidian investment? - The investment aligns with Himax's technology, enhancing thermal imaging capabilities and offering unique applications [63][64]

Americold Realty Trust (COLD) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Kevin Reed - VP of Investor RelationsGeorge Chappelle - Chief Executive OfficerRobert Chambers - President of AmericasJay Wells - Executive VP & Chief Financial OfficerSamir Khanal - DirectorGreg Mcginniss - DirectorKi Bin Kim - Managing DirectorMichael Carroll - Managing Director & Head of US Real Estate ResearchVince Tibone - Managing Director and Head of US Industrial & Mall Research Conference Call Particip ...

Financial Data and Key Metrics Changes - Total revenue grew 22% year over year to $106.5 million in Q1 2025, driven by increased sales for VivGuard, Zejula, and NUZYRA [29][30] - Operating loss improved by 20% to $56.3 million, and adjusted loss from operations decreased by 25% to $37.1 million [16][30] - The company reaffirmed its full-year revenue guidance of $560 million to $590 million, anticipating significant sales growth in the latter part of the year [8][30] Business Line Data and Key Metrics Changes - VivGuard sales are expected to grow faster than total revenue growth, with a rebound in patient volumes observed in March and April after a seasonal decline [12][36] - Other products, including Zejula and NUZYRA, delivered sequential growth supported by NRDL access, with early contributions from OGTYRO and ZACDURO [15] - The company is preparing for upcoming NRDL cycles targeting IV renewal for gMG and initial listing of the SC formulation [14] Market Data and Key Metrics Changes - The company noted a significant opportunity in the gMG market in China, with approximately 70,000 patients, and less than 10% currently receiving newer biologic therapies [63] - The competitive landscape for gMG is expected to benefit from the introduction of new therapies, which will enhance overall market education and treatment options [63] Company Strategy and Development Direction - The company aims to expand its global R&D pipeline, with a focus on differentiated and high-potential assets, including GL1310 and other novel therapies [9][10] - Investments are being made to accelerate the global R&D pipeline, with plans to present updated Phase I data at ASCO [10][20] - The company is committed to achieving profitability by Q4 2025, leveraging operational efficiencies and a robust late-stage opportunity pipeline [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue targets and surpassing $2 billion by 2028, with strong momentum expected to carry into the 2030s [9] - The management team highlighted the importance of strategic initiatives to extend treatment duration and improve patient access [12][14] - The company remains optimistic about its financial position, ending Q1 with a cash position of $857.3 million [31] Other Important Information - The company is advancing its internal pipeline while also considering external opportunities for in-licensing [102][103] - Regulatory discussions with the FDA are ongoing, with no significant changes noted in the approval process despite recent leadership changes at the FDA [53][105] Q&A Session Summary Question: Can you provide more color on VIBGART's sequential change? - Management indicated that the sequential decline was influenced by seasonality and inventory dynamics, with confidence in recovery based on strong patient volumes in April [33][36] Question: Are you comfortable with consensus estimates for VIBGART and fiscal year revenues? - Management reaffirmed their revenue guidance and expressed confidence that VIBGART sales would grow faster than overall business rates [42][44] Question: How do recent FDA changes impact Zai Lab? - Management noted no anticipated impact from tariffs and indicated that FDA interactions have remained productive [50][53] Question: What is the competitive landscape for gMG in China? - Management believes that new approvals will benefit the market and enhance treatment options for patients [63] Question: What is the strategy regarding in-house developed assets? - The company plans to maintain a balanced approach between in-house development and external licensing opportunities [102][103]